FATE THERAPEUTICS INC(NASDAQ:FATE) stock News

FATE Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill

FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss

4 days ago - By: Zacks Investment Research - Mentions: RNA

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

4 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

4 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

5 days ago - By: Zacks Investment Research - Mentions: ENTA

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

9 days ago - By: Zacks Investment Research - Mentions: HCAT

Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates

10 days ago - By: Zacks Investment Research - Mentions: VRDN

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

11 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

11 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

3 months ago - By: Fate Therapeutics, Inc. - Mentions: NBIX

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

3 months ago - By: Zacks Investment Research - Mentions: HALO ALLO

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

3 months ago - By: Benzinga

4 Analysts Assess Fate Therapeutics: What You Need To Know

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

4 months ago - By: Fate Therapeutics, Inc.